Physician profile
Paul D Burrows
NPI 1023002748
$3,008.43
in general payments reported to CMS, 2019-2025
26 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $684 · 2021: $252 · 2022: $110 · 2023: $54.78 · 2024: $343 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $628.54 | 2019-2025 | |
| Abbvie INC. | $509.45 | 2019-2025 | |
| Janssen Biotech, INC. | $253.68 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $231.60 | 2019-2025 | |
| Gilead Sciences, INC. | $230.76 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.01 | 2019-2020 | |
| Capsovision, INC. | $158.25 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $156.97 | 2019-2021 | |
| Ucb, INC. | $52.78 | 2019 | |
| Ferring Pharmaceuticals INC. | $44.30 | 2021-2022 | |
| Medtronic, INC. | $38.14 | 2021-2023 | Gi Genius |
| Qol Medical, LLC | $36.96 | 2019-2025 | Sucraid |
| Micro-Tech Endoscopy USA, INC. | $26.15 | 2024 | Lesionhunter |
| Concordia Pharmaceuticals INC. | $24.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $23.92 | 2025 | Single Use Repositionable Clip |
| Mauna Kea Technologies, INC. | $21.39 | 2024 | |
| Redhill Biopharma INC. | $21.37 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.92 | 2025 | Voquezna |
| Endo Pharmaceuticals INC. | $19.07 | 2020 | |
| Omeros Corporation | $19.00 | 2020 | |
| Novo Nordisk INC | $17.78 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $16.33 | 2023 | |
| Axonics, INC. | $14.60 | 2024 | Axonics |
| Ironwood Pharmaceuticals, INC | $14.21 | 2019 | |
| Merck Sharp & Dohme LLC | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.